Consistent with the synergistic inhibition of the growth of cervical cancer by targeting MTCH1 in combination with sorafenib treatment,[62] we found that MTCH2 knockout synergistically facilitates the antitumor activity of sorafenib in CRC liver metastasis, indicating that the MTCH2 knockout and sorafenib had effects partially on distinct pathways. The gene discussed is MTCH2; the disease is cervical cancer.